Full-Time

FP&A Manager

Freenome

Freenome

201-500 employees

Blood-based multiomics cancer detection tests

Compensation Overview

$146.8k - $183.8k/yr

+ Equity + Bonus

Daly City, CA, USA

Hybrid

Category
Finance & Banking (1)
Required Skills
NetSuite
Forecasting
Machine Learning
Data Analysis
Excel/Numbers/Sheets
Financial Modeling
Requirements
  • Bachelor’s degree in Accounting/Finance/Business.
  • Minimum of 8 years of progressive Accounting and Finance experience with at least 6 in FP&A and/or business partnering in a fast-paced, high-growth biotech, diagnostic, medical device environment.
  • Willingness to roll up your sleeves, handle large amounts of data and build complex financial models.
  • Excellent organizational and analytical skills with the ability to creatively solve problems with a data-driven approach.
  • Ability to articulate complex financial concepts in understandable terms to non-finance professionals.
  • Demonstrated ability to think strategically while maintaining a command of the details.
  • Demonstrated ability to develop client group business acumen and provide actionable insights and recommendations to improve KPIs.
  • Mastery of Excel and ERP systems (e.g. Netsuite) and proven experience implementing or optimizing FP&A software and a demonstrated interest in AI-driven analytics.
  • Passion for automation and continuous improvement to reduce human error and dependency on spreadsheets.
  • Proven experience building financial management processes, management reporting, and establishing the financial discipline required in a scaling organization.
  • Well-versed in the requirements of a public company and adherence to all applicable laws, rules, and regulations.
Responsibilities
  • Serve as the dedicated financial advisor to department heads (R&D, Commercial, Operations), translating complex financial data into a narrative that drives decision-making.
  • Identify financial opportunities by deeply understanding the drivers of our diagnostic platform and product offerings.
  • Drive corporate planning processes through rigorous oversight of departmental budgets and forecasts, ensuring alignment with Freenome’s strategic priorities.
  • Empower budget owners with self-service tools while providing the “guardrails” necessary for a public company environment.
  • Deliver effective monthly and quarterly reporting that drives accountability, scaled by leveraging technology.
  • Establish, track, and report Key Performance Indicators (KPIs) specific to a commercial-stage diagnostic company, such as test volume, ASP, and COGS per test.
  • Ensure resources are aligned with strategic and operating priorities and clear financial controls are maintained.
  • Identify key business issues that impact short-term and long-range market forecasts; clearly and proactively surface these issues.
  • Influence key decisions by delivering high value financial analysis that highlight root causes of variance, trends, and identify actionable opportunities to invest, reduce costs, and mitigate risks.
  • Build and refine the forecasting tools, short-term and long-term forecasts models.
  • Support the implementation, buildout and continuous improvement of key financial systems, such as ERP, planning and budgeting systems and business Intelligence tools.
  • Apply AI and machine learning tools to automate routine reporting and enhance predictive accuracy in our forecasting models.
  • Collaborate with the broader organization to drive process and systematic improvements across the Company.
Desired Qualifications
  • MBA/CPA or CFA a plus.
  • Experience as a FP&A professional for single-site labs (FDA/CLIA diagnostics business) and/or reagent manufacturing environments.
  • Knowledge of clinical diagnostics development, operations, portfolio management and commercial GTM planning.

Freenome develops non-invasive blood tests for early cancer detection by combining genomics and proteomics to identify cancer signals in blood. The tests are sold to healthcare providers and research institutions and are also used in clinical trials and collaborations. The process involves analyzing a blood sample with proprietary algorithms to assess cancer risk and guide follow-up diagnostics. By integrating multiple data types and pursuing large-scale trials, Freenome aims to make early cancer screening routine and improve patient outcomes, with a focus on expanding colorectal cancer testing.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • SimpleScreen CRC FDA approval expected H2 2026 unlocks $2B+ colorectal cancer screening market.
  • SPAC merger with Perceptive Capital Solutions provides $330M funding for multi-cancer pipeline expansion.
  • Roche $75M investment and $200M+ deal validates technology and accelerates global commercialization.

What critics are saying

  • Exact Sciences exclusive U.S. rights eliminate Freenome's domestic revenue and commercialization control.
  • SPAC merger failure depletes cash reserves after 100-employee layoffs, halting product launches.
  • Guardant Health's Shield test captures 70% market share, undercutting Freenome's multiomics platform.

What makes Freenome unique

  • Multiomics platform analyzes DNA, immune, and metabolic signals for earliest cancer detection.
  • Secured exclusive U.S. colorectal cancer rights deal with Exact Sciences worth up to $775 million.
  • Roche partnership enables kitted decentralized testing and Axelios sequencing technology evaluation internationally.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Freenome who can refer or advise you

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-3%
BioPharma Dive
Nov 20th, 2025
Roche inks deal for rights to Freenome cancer tests outside US

Roche inks deal for rights to Freenome cancer tests outside US. Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round. Dive brief: * Roche has struck a deal to commercialize Freenome's cancer screening technology outside the U.S., the companies said Tuesday. * Freenome will receive a $75 million investment from Roche as part of a deal that could be worth more than $200 million. * The deal positions Freenome, which currently uses Illumina machines, to evaluate Roche's new sequencing device. In a note to clients, Leerink Partners analysts said they see no near- to medium-term impact on Illumina. Dive insight: Nearing pre-market approval of its colorectal cancer blood-based screening test, Freenome has struck deals to support its commercialization in recent months. In August, Exact Sciences agreed to pay Freenome $75 million upfront, plus up to $700 million in milestones, for U.S. rights to current and future versions of the test. Roche's deal covers the marketing of "kitted" tests in areas outside of the U.S. Kitted tests package the software and assay to enable decentralized test processing and analysis, eliminating the need for a singular large processing lab. Freenome has retained rights to centralized testing outside the U.S. Roche, meanwhile, could shell out milestone payments and royalties on ex-U.S. sales. The $75 million equity investment increases Roche's stake in Freenome after leading a $254 million financing round last year. Other Roche investments, such as positions backing Flatiron Health and Foundation Medicine, have resulted in acquisitions. Freenome already uses Roche's Elecsys technology for multiple types of analyses. Under the new deal, Freenome will study the potential for Roche's "sequencing by expansion" technology to enhance its cell-free DNA cancer screening tests. Freenome will also gain access to Roche plasma sample cohorts to support the development of personalized screening tests for multiple types of cancer. Roche unveiled its sequencing technology in February and provided more information at its diagnostics day in May. At that event, Josh Lauer, the company's head of molecular labs, said "speed is something very unique about this platform and something no other short-read sequencer is able to match." Leerink analysts evaluated the threat the technology - which Roche has branded Axelios - poses to Illumina in light of the Freenome agreement. The analysts said the deal "highlights Roche's long-term strategy for Axelios - a clinical box for running NGS kits, similar to with their prior success in IVD kits." Yet it will take a few years of testing and refinement to ready Axelios for clinical sequencing, they added. "We don't expect other oncology Dx companies to jump to try Roche SBX in [the] U.S. or internationally given their new assays are already entrenched and some are FDA approved on [Illumina] sequencers," the analysts said in a note to investors. "Switching costs and reliability needs are high and clinical Dx companies indicate they won't entertain the switch without a clear value proposition."

Freenome
Nov 19th, 2025
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.

– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially […]

finanzen.net
Nov 18th, 2025
Freenome, Roche Partner in $200M Deal

Freenome has partnered with Roche in a deal potentially worth over $200 million to commercialize its cancer screening technology in international markets. The agreement includes a $75 million equity investment from Roche and focuses on developing "kitted" tests for decentralized processing. Freenome will also evaluate Roche's Sequencing by Expansion technology. This collaboration aims to enhance Freenome's multiomic blood-based cancer screening platform and expand its global reach.

PR Newswire
Jun 2nd, 2025
Freenome Announces Jama Publication Of Data From Pivotal Study Of Its Blood-Based Test For Colorectal Cancer

– PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population –. – FDA premarket approval submission is underway, with completion anticipated mid-2025 –. BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication presents findings from the largest prospective study of a blood-based screening test for colorectal cancer (CRC), involving 48,995 average-risk adults aged 45 to 85 who underwent a routine colonoscopy following a blood draw

Health Technology Insights
May 21st, 2025
Freenome Appoints Linh H. Le as Chief Financial Officer

Freenome appoints Linh H. Le as chief financial officer.